Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
301-320 of 998 trials

Familial Mediterranean Fever: On-Demand Anakinra Treatment

We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.

Familial Mediterranean Fever>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious DiseasesInternal MedicineRheumatology

Duchenne Muscular Dystrophy: BMN 351 Treatment Study

We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Solid Tumors: AZD3470 Study

We are testing a new drug, AZD3470, for patients with advanced solid tumors lacking the MTAP gene. The study aims to evaluate its safety and effectiveness, both alone and with other cancer treatments.

Advanced Metastatic Solid Tumors (MTAP Deficient)Safety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Spinal Muscular Atrophy: RO7204239 with Risdiplam

We are studying the safety and effectiveness of a new treatment combining RO7204239 with risdiplam for individuals with spinal muscular atrophy. This trial will help us understand how well this combination works compared to a placebo.

Spinal Muscular Atrophy (SMA)1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessPartially RemoteInternal MedicineNeurology

Lung Cancer: Selpercatinib Study

We are testing a new treatment called selpercatinib for patients with RET fusion-positive non-small cell lung cancer. The goal is to see if it improves outcomes compared to a placebo.

RET Fusion-Positive Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Pulmonary Hypertension: Long-term Safety Study

We are evaluating the long-term safety of treatments for pulmonary hypertension in participants who have previously received these interventions. This study aims to ensure ongoing safety for those already involved in related research.

Pulmonary HypertensionConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Neurodegenerative Disease: Continued Access to Latozinemab

We are offering ongoing access to the medication latozinemab for individuals with neurodegenerative diseases who have participated in earlier studies. The trial will monitor safety and any clinical benefits from continued treatment.

Neurodegenerative DisordersConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Recurrent Gynecological Cancers: IMGN151 Study

We are testing a new drug, IMGN151, in women with recurrent gynecological cancers to assess its safety and determine the best dose. This study aims to understand how well the drug works and its effects on patients.

Recurrent Gynecological Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Chronic Hepatitis B: Long-Term Study on Treatment Response

We are investigating how well previous participants of a hepatitis B treatment maintain their health over time. This study focuses on those who have stopped certain therapies and aims to understand their long-term outcomes.

Chronic Hepatitis BEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInfectious Diseases

Heart Attack Recovery: Ziltivekimab Study

We are investigating how ziltivekimab may improve heart health in people who have had a heart attack compared to a placebo. This study aims to see if it can reduce serious heart-related issues.

Heart Attack>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Lung Cancer: Durvalumab and Domvanalimab Study

We are studying a combination of two medications for patients with stage III unresectable non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this combination improves survival and disease control compared to standard treatment.

Lung Cancer6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Follicular Lymphoma: Epcoritamab with Rituximab and Lenalidomide

We are studying a new treatment combination for adults with previously untreated follicular lymphoma. The goal is to see if it works better and has fewer side effects than standard chemotherapy.

Follicular LymphomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Oocyte Donation: Corifollitropin alfa vs. Daily rFSH

We are studying whether Corifollitropin alfa can help increase the number of eggs collected from oocyte donors compared to standard daily treatments. This trial involves women using hormone suppression to improve egg quality.

Female Infertility1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and Obstetrics

Ulcerative Colitis: Novel Rifamycin Enema

We are testing a new rifamycin solution for patients with mild to moderate left-sided ulcerative colitis. The study aims to see if it helps improve symptoms and induce remission compared to a placebo.

Left-Sided Ulcerative Colitis3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Stroke Treatment: Intra-Arterial Thrombolysis Study

We are studying whether adding a specific clot-dissolving treatment helps improve recovery in patients with acute strokes who have already had successful blood flow restoration. This trial will also evaluate safety and costs associated with this treatment.

Ischemic Stroke1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyNeurology

Gene Therapy for Crigler-Najjar Syndrome: GNT0003

We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.

Crigler-Najjar Syndrome>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteHepatology

Coronary Artery Disease: Angiolite Stent and Antiplatelet Therapy Study

We are evaluating whether a new stent and a shorter antiplatelet therapy can reduce complications in patients with coronary artery disease. This study compares these approaches to standard treatment options.

Coronary Artery Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiology

Dilated Cardiomyopathy: Candesartan vs Placebo

We are studying whether early treatment with candesartan can help prevent heart function decline in people with a genetic risk for dilated cardiomyopathy who currently have no symptoms. The trial also looks at the safety of this medication.

Dilated Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Viral Lung Infection: Tozorakimab Study

We are testing the new medication tozorakimab in patients hospitalized for viral lung infections requiring oxygen. The goal is to see if it can help prevent serious complications compared to a placebo.

Acute Respiratory FailureSevere Viral Lung Infections≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Plaque Psoriasis: JNJ-77242113 Treatment Study

We are studying a new medication for people with moderate to severe plaque psoriasis. The goal is to see if it works better than a placebo in reducing symptoms.

Plaque Psoriasis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteDermatology